Silencing of both beta-TrCP1 and HOS (beta-TrCP2) is required to suppress human immunodeficiency virus type 1 Vpu-mediated CD4 down-modulation - Test2 - elhamkhani - TriplyDB

Silencing of both beta-TrCP1 and HOS (beta-TrCP2) is required to suppress human immunodeficiency virus type 1 Vpu-mediated CD4 down-modulation

Silencing of both beta-TrCP1 and HOS (beta-TrCP2) is required to suppress human immunodeficiency virus type 1 Vpu-mediated CD4 down-modulation

http://www.wikidata.org/entity/Q24675781

about

HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent degradation Multilayered mechanism of CD4 downregulation by HIV-1 Vpu involving distinct ER retention and ERAD targeting steps Antiviral inhibition of enveloped virus release by tetherin/BST-2: action and counteraction Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a {beta}TrCP-dependent mechanism HIV-1 accessory protein Vpu internalizes cell-surface BST-2/tetherin through transmembrane interactions leading to lysosomes NMR structural characterization of HIV-1 virus protein U cytoplasmic domain in the presence of dodecylphosphatidylcholine micelles Modulation of HIV-1-host interaction: role of the Vpu accessory protein The Vpu protein: new concepts in virus release and CD4 down-modulation Direct internalization of cell-surface BST-2/tetherin by the HIV-1 accessory protein Vpu Viral miniproteins Transmembrane domain determinants of CD4 Downregulation by HIV-1 Vpu.Ubiquitination of BST-2 protein by HIV-1 Vpu protein does not require lysine, serine, or threonine residues within the BST-2 cytoplasmic domain.A small molecule compound IMB-LA inhibits HIV-1 infection by preventing viral Vpu from antagonizing the host restriction factor BST-2.Host restriction factors in retroviral infection: promises in virus-host interaction.Conserved residues within the HIV-1 Vpu transmembrane-proximal hinge region modulate BST2 binding and antagonism.HIV-1 Vpu affects the anterograde transport and the glycosylation pattern of NTB-A.HIV-1 Vpu blocks recycling and biosynthetic transport of the intrinsic immunity factor CD317/tetherin to overcome the virion release restriction β-TrCP is dispensable for Vpu's ability to overcome the CD317/Tetherin-imposed restriction to HIV-1 release.Identification of amino acids within the second alpha helical domain of the human immunodeficiency virus type 1 Vpu that are critical for preventing CD4 cell surface expression.Modulation of beta-catenin and E-cadherin interaction by Vpu increases human immunodeficiency virus type 1 particle release.Downmodulation of CCR7 by HIV-1 Vpu results in impaired migration and chemotactic signaling within CD4⁺ T cells.Interferon-induced SCYL2 limits release of HIV-1 by triggering PP2A-mediated dephosphorylation of the viral protein Vpu.βTrCP is Required for HIV-1 Vpu Modulation of CD4, GaLV Env, and BST-2/Tetherin

P2860

Q21089617-F451B90F-9958-4FC9-B57D-4C6E637F4C6B Q21131559-86957A79-3B2D-4CF6-9610-A784271D6907 Q24635271-DF830B08-2D8F-4ECF-9C13-1B595B989314 Q24644811-CDF0DA38-5958-421F-A588-8F10F5FDF6D1 Q24646984-A9B1A114-98FF-4D78-8E1E-8CDC8A0C3111 Q27657668-39B54E98-0425-49A6-BE9C-31AAF039F353 Q30397761-9E059E5E-A700-4B72-936E-E871F08B461B Q34021500-854578F4-00CA-405B-B870-1E83A1EEBE4F Q34084429-8A80A14C-A1EB-4775-AAE3-2F5E85092F33 Q35151120-EFB55CB5-D669-4829-BE61-C22856A6727B Q35665886-FC05FDD3-1846-4196-A055-B02F08EDE2C4 Q35922462-41AA39CB-20F4-4424-9922-4E8965CF3C84 Q36376142-32222E05-F5F3-46F5-B959-1D94BA959A16 Q36548179-C5859A65-6EB1-4939-AC77-341D3344AA75 Q38910738-FF2B2FD4-12E2-4EB2-8F9B-A97E26BDD08E Q39175785-9AD5EB42-66D1-4ACE-8096-F4CA052D5AB8 Q39536992-EA347EA9-3F46-4F65-B821-6871781A3AE3 Q39594626-17BF4338-8235-4698-BED6-5EDC4B7949A9 Q39769799-E96A1C8F-E66C-445E-92EA-F4F55BC63416 Q40015792-4286AAD8-CED9-4CAD-AB7B-FF2CF433A019 Q42211475-17438E08-3332-4048-A4A6-E1E584A0FDC9 Q54478839-B09D68A6-5633-465D-B862-50CA2D9FB5DD Q57811810-6CAF4428-62B7-4E73-905B-9C3173750382

P2860

Silencing of both beta-TrCP1 and HOS (beta-TrCP2) is required to suppress human immunodeficiency virus type 1 Vpu-mediated CD4 down-modulation

http://www.wikidata.org/entity/Q24675781

description

2007 nî lūn-bûn

@nan

2007 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Silencing of both beta-TrCP1 a ...... u-mediated CD4 down-modulation

@ast

Silencing of both beta-TrCP1 a ...... u-mediated CD4 down-modulation

@en

Silencing of both beta-TrCP1 a ...... u-mediated CD4 down-modulation

@nl

type

label

Silencing of both beta-TrCP1 a ...... u-mediated CD4 down-modulation

@ast

Silencing of both beta-TrCP1 a ...... u-mediated CD4 down-modulation

@en

Silencing of both beta-TrCP1 a ...... u-mediated CD4 down-modulation

@nl

prefLabel

Silencing of both beta-TrCP1 a ...... u-mediated CD4 down-modulation

@ast

Silencing of both beta-TrCP1 a ...... u-mediated CD4 down-modulation

@en

Silencing of both beta-TrCP1 a ...... u-mediated CD4 down-modulation

@nl

P1433

Q24675781-EAA16D0B-2FFE-4720-A5B3-0996B5344129

P1476

Q24675781-5F3E49A9-58C8-4C4C-B0EA-A037CC57C557

P2093

Q24675781-0B86CEB3-6649-401C-B878-4F1EE7DCB833

Q24675781-13CD1AC7-183D-4EA8-B512-977ED89341AF

Q24675781-77B2F1DE-A934-4DFA-81DB-A2E4D8021A7C

Q24675781-95D88AFD-B96D-417B-8389-0E9DA452A223

P2860

Q24675781-007BA23B-AD37-4470-B717-48D7BDDB1D93

Q24675781-2A3C90B8-3D73-437E-BF8B-0FC6B35315B8

Q24675781-2C8E6D56-89A3-41BD-8B39-F8292C9E6F91

Q24675781-3336F98F-93D6-4E4A-A6B5-A66580254F87

Q24675781-36F9EC3C-51F6-4C69-B28F-A4B17A39288D

Q24675781-3A23C825-4140-4952-AEA4-05E6ADBAE336

Q24675781-4CAA81E2-BBAE-4D2D-AF70-42E923EBEDBA

Q24675781-4D31F378-9388-4317-AE16-9EE41207A1FC

Q24675781-505B3779-FD39-4B94-83BC-A89709378986

Q24675781-5310958B-D2ED-4C84-A5A4-EDA0E839208F

P304

Q24675781-7B40127C-BA16-434E-8E92-C70837AAF407

P31

Q24675781-F4A3EFE2-FBBA-481E-9BB2-F1D84DD0B672

P356

Q24675781-334F6E79-5654-4390-AE20-FBF0F3909806

P407

Q24675781-69C1BF04-428A-43DB-910F-9BA2760814E0

P433

Q24675781-6493AA2E-35B3-4632-9076-4C503C37B221

P478

Q24675781-08D1DBD3-8405-4315-B36A-1BFC6A00F99B

P50

Q24675781-E9AD63DD-9BA2-481D-8512-A3320DE908F6

P577

Q24675781-5F3293A3-5CC2-4AAB-8F6C-EEA5A9405BD6

P5875

Q24675781-790CCD93-62E7-491A-81DA-FCC82E9BDEBE

P698

Q24675781-071287E6-08AF-4467-A871-A578EED3221E

P921

Q24675781-AE4A3857-2AC5-46CA-82B4-7FEDC67E9A6D

P932

Q24675781-332596F6-7E87-41E7-895A-BAEE2A3C82F3

P356

P1433

Journal of Virology

P1476

Silencing of both beta-TrCP1 a ...... u-mediated CD4 down-modulation

@en

P2093

Christophe Butticaz

http://www.w3.org/2001/XMLSchema#string

Josiane Wyniger

http://www.w3.org/2001/XMLSchema#string

Olivier Michielin

http://www.w3.org/2001/XMLSchema#string

Sylvia Rothenberger

http://www.w3.org/2001/XMLSchema#string

P2860

Signal-induced ubiquitination of IkappaBalpha by the F-box protein Slimb/beta-TrCP

Identification of the receptor component of the IkappaBalpha-ubiquitin ligase

Identification of a family of human F-box proteins

An F-box protein, FWD1, mediates ubiquitin-dependent proteolysis of beta-catenin

The SCFbeta-TRCP-ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in IkappaBalpha and beta-catenin and stimulates IkappaBalpha ubiquitination in vitro

Differential activities of the human immunodeficiency virus type 1-encoded Vpu protein are regulated by phosphorylation and occur in different cellular compartments

The human immunodeficiency virus type 1 accessory protein Vpu induces apoptosis by suppressing the nuclear factor kappaB-dependent expression of antiapoptotic factors

The human immunodeficiency virus type 1 Vpu protein specifically binds to the cytoplasmic domain of CD4: implications for the mechanism of degradation

The human F box protein beta-Trcp associates with the Cul1/Skp1 complex and regulates the stability of beta-catenin.

betaTrCP-mediated proteolysis of NF-kappaB1 p105 requires phosphorylation of p105 serines 927 and 932.

P304

1502-5

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/JVI.01711-06

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

81

http://www.w3.org/2001/XMLSchema#string

P50

P577

2007-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6675850

http://www.w3.org/2001/XMLSchema#string

P698

17121803

http://www.w3.org/2001/XMLSchema#string

P921

P932

1797504

http://www.w3.org/2001/XMLSchema#string